Adam Vojtěch has been Minister of Health of the Czech Republic since December 2025, having previously led the ministry from 2017 to 2021. He studied law and media studies at Charles University and spent a year at University College Dublin. He began his career as an in-house lawyer at Mafra, then joined the Ministry of Finance, focusing on healthcare regulation and financing and the oversight of health insurers. As minister, he introduced e-prescriptions and reforms of primary and mental health care. From 2022 he headed the Czech Embassy in Helsinki and in October 2025 was re-elected to the Chamber of Deputies.

Stefan Oelrich is a member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division, based in Berlin. Appointed in 2018, he has led a transformation of the division, focusing on healthcare innovation. He first joined Bayer in 1989, holding senior leadership roles in Latin America, Europe and the United States. He later spent seven years at Sanofi, leading its German-speaking region before building its diabetes and cardiovascular business and joining its Executive Committee in 2016. He has sat on the Supervisory Board of Charité since 2020 and has been President of EFPIA since June 2025.

Jan Sechter has been Deputy Minister of Industry and Trade since 2026. He studied economics at the Czech University of Life Sciences Prague and attended the German Foreign Office’s Diplomatic Academy. A career diplomat, he was Deputy Head of Mission in Germany and Ambassador to Poland and Austria (2008–2017). He later advised the Speaker of the Chamber of Deputies, served as Deputy Minister of Transport (2020–2022) and was the government coordinator for the Three Seas Initiative. He chaired the Transport Section of the Czech Chamber of Commerce and worked for Primoco UAV and the Central European Industry Partners fund.

Since 2020, he has been working at the Chamber of Commerce, where he serves as Vice-President. His term of office was most recently confirmed by the Chamber's Assembly in April 2026. He has been President of the Czech Confederation of Commerce and Tourism since October 2018 and Vice-President of the European trade association EuroCommerce since 2019. Between 2004 and 2006, he served as Deputy Minister of Finance. He subsequently worked in the banking sector and as an expert for the World Bank. Between 2014 and 2017, he was State Secretary for European Affairs and Coordinator of the Czech Republic's Digital Agenda. His areas of focus include the business environment, trade, the labour market, European policy and healthcare funding.

Anna Arellanesová has been Chair of the Rare Diseases Czech Republic, an umbrella organisation for patient organisations focused on rare diseases, since 2014. She is also a committee member and former Chair of the Czech Cystic Fibrosis Association. She served two terms as Vice-Chair of the Minister of Health’s Patient Council, where she continues to represent rare diseases as a member. She also sits on the Board of Directors of EURORDIS, the European umbrella patient organisation. She contributed to drafting new legislation on the reimbursement approval system for medicinal products for rare diseases, which provides for the active participation of patients as decision-making stakeholders. She is also a member of the Interministerial Commission for Rare Diseases at the Ministry of Health. Through long-term cooperation with experts, she helped prepare and continues to implement the National Strategy for Rare Diseases and its follow-up implementation plans.

David Kolář is Executive Director of the Association of Innovative Pharmaceutical Industry (AIFP), where he has worked for more than ten years. Appointed to the role in 2022, he is responsible chiefly for the association’s strategic management, development activities and the delivery of its goals. He has long focused on access to modern treatment, medicines policy and reimbursement of innovative therapies, promoting cooperation between the state, health insurers, patient organisations and the pharmaceutical industry. He also contributes to strategic discussions on the future of healthcare funding, the digitalisation of the system and the development of innovation in Czech healthcare.